ARTICLE | Clinical News
NaPro regulatory update
January 30, 1995 8:00 AM UTC
NaPro BioTherapeutics Inc. (NPRO) NPRO’s paclitaxel ( taxol) product received approval in Australia to treat advanced refractory ovarian and breast cancers. NPRO’s marketing partner, F. H. Faulding & ...